Abstract It has been recognized that, in addition to its classical function, vitamin D modulates a variety of processes and regulatory systems including host defense, inflammation, and immunity. Some authors concluded that there is strong relation between vitamin D serum level and lung functions but others concluded that there is no relation between them.
Introduction
The role of vitamin D in calcium and bone homeostasis is well described. In the last years, it has been recognized that, in addition to its classical function, vitamin D modulates a variety of processes and regulatory systems including host defense, inflammation, and immunity and repair, especially patients with lung diseases often have low vitamin D serum level. Epidemiological data indicated that low serum level of vitamin D is associated with impaired pulmonary function, increased incidence of inflammatory infectious or neoplastic diseases [1] . Recently, the connection between vitamin D status and COPD has attracted attention [2] . Some authors concluded that there was a strong relationship between serum level of vitamin D and lung functions. In contrast, others did not find any relation between them [3] . Cathelicidin LL-37 is the only member of the cathelicidin family of host defense peptides that is expressed in humans. It is a linear 37 amino acid peptide produced from the C-terminus of hCAP18 precursor protein by a proteolytic cleavage [4] . LL-37 is produced by phagocytic leucocytes and other cells, it is a major constituent of zurophilic granules of neutrophils, it has direct antimicrobial action and diverse immuno-modulatory properties [5, 6] . Importantly, the production of LL-37 in human primary monocytes in response to infection is dependent on 1.25 vit D3 either exogenously supplemented in ex vivo systems or naturally present in human serum [7] . In addition to the widely recognized role of 1.25 vit D3 in antimicrobial immunity, it is also known to have anti-inflammatory activity, suppressing the intentions of TNFa, IFNc and IL12 p40 [8] . Thus, the recently established role of 1.25 vit D3 in LL-37 induction further reinforces the notion that LL-37, may function in the context of ''non classical'', non inflammatory responses to infection. Possible contributions of LL-37 to the anti-inflammatory activity of the 1.25 vit D3 system remain to be investigated [9] .
Aim of the work
Is to study the role of serum level of 25 hydroxy-vitamin D in COPD patients through the assessment of the serum levels of vitamin D dependent LL-37 and IFNc and to study the link between the three parameters and pulmonary functions in these patients.
Patients and methods
This work included 40 persons collected from the outpatients chest clinic in the Tanta University hospitals in the period from February to May 2013 and were divided into two groups.
Group I: Included 10 apparently healthy non smoker volunteers, 7 males and 3 females, and their mean ages were 40 ± 3 years.
Group II: Included 30 COPD patients, 26 males and 4 females and their mean ages were 52 ± 2.5 years.
COPD patients should fulfill the following criteria
Patients were non smokers or exsmokers (for at least 1 year) and had a history of COPD. FEV1/FVC < 70%, % of recovery after bronchodilator therapy is <15%, X-ray chest PA view develops hyperinflation and X-ray chest ''lateral view'' showed retrosternal airspace >2.5 cm if measured form anterior border of ascending aorta to posterior border of manubrium sterni.
Exclusion criteria were
If patients had bronchial asthma, other chronic lung diseases or history of upper or lower respiratory tract infections in the last month, history of vitamin D supplements within 1 month and acute exacerbation of COPD.
All persons were subjected to full history taking and full clinical examination. Plain chest X ray (PA and lateral views), Table 2 and Fig. 2 showed that mean values of serum level of 25 hydroxy vitamin D in groups I and II were 181.32 ± 4.48 and 64.12 ± 3.61 respectively. There was a significant decrease in group II as compared to group I (p < 0.05). Table 3 and Fig. 3 showed that mean values of serum level of LL-37 in groups I and II were 97.14 ± 1.8 and 25.36 ± 3.07 ng/ml respectively. There was a significant decrease in group II as compared to group I (p < 0.05). Table 4 and Fig. 4 showed that mean values of serum level of IFNc in groups I and II were 14.35 ± 1.31 and 63.65 ± 7.95 pg/ml respectively. There was a significant increase in group II as compared to group I (p < 0.05). Figure 3 Mean, standard deviation and statistical analysis of serum level of LL-37(ng/ml) in GI and GII. Figure 4 Mean, standard deviation and statistical analysis of serum level of IFNc (pg/ml) in GI and GII.
Does serum 25 hydroxy vitamin D level play a role in COPD?
vitamin D and both FEV1 and FVC [2] . Janssens et al. showed a nearly identical relationship between airway obstruction and vitamin D level [11] . A similar association between 25 hydroxy vitamin D and FEV1, has been reported in adults with asthma [12] . Vitamin D has several functions, in addition to bone mineralization, vitamin D has been shown to be an important regulator of both elements of the immune system, has a role in dendritic cell maturation [13] , T cell activation and proliferation [14] and Th1 T cell development [15] , decrease the susceptibility to respiratory infections, decrease the expression of pro-inflammatory cytokines and chemokines [16] . Vitamin D has been shown to directly affect processes involved in tissue remodeling such as fibroblast proliferation and collagen synthesis and modulation of matrix metalloproteinase levels [17] . Undiagnosed osteoporosis leading to vertebral compression may lead to loss in height, reduced rib cage mobility and decline in pulmonary function [18] . Patients with COPD should be considered at high risk of vitamin D insufficiency because of reduction of outdoor activity, increased glucocorticoids induced catabolism, impaired activation as a consequence of renal dysfunction, and a lower storage capacity in muscle and fat due to wasting [19] . Franco et al., concluded that severity of COPD was related to low vitamin D level [20] . In contrast, Bjerk et al., found that in severe COPD patients, 2000 iu of daily vitamin D for 6 weeks increased 25 hydroxy vitamin D level widely considered as normal, however, compared with placebo, vitamin D supplementation has no discernible effect on short physical performance Battery scorer and St. Georges Respiratory question the naive score [21] . 1,25 dihydroxy vitamin D is essential for induction of LL-37 through intracellular vitamin D receptor as well as steroid receptor co-activator and histone acetylation [22] . In our study, there was a decrease in vitamin D level and LL-37 level which had several actions, microbiocidal activity, suppressing the induction of TNFa, IFN c and IL12p 40, inhibits formation of pseudomonas aeriginosa biofilms, suppress of LPS-induced production of inflammatory cytokines, neutrophils apoptosis which may play a role in pathogenesis of COPD [23, 9, 24] . Lemire concluded that active vitamin D metabolite 1,25 dihydroxy vitamin D3 promotes many of its actions through interaction with specific intra cellular receptor located in monocytes and activated lymphocytes which leads to the concept that vitamin has a role in immune system. Sterol inhibits lymphocyte proliferation and immunoglobulin production in a dose-dependent fashion, at a molecular level q,25-D3 inhibits the accumulation of MRNA for IL-2, IFNc and GM-CSF [25] so, this study concluded that vitamin D deficiency leads to reduction in lung functions in 
